Amneal Pharmaceuticals In... (AMRX)

For my initial rating of Amneal Pharmaceuticals (AMRX), I am calling it a buy. I was impressed by its large, diversified portfolio of therapies across clinical segments, and active pipeline of future ...

The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...

The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positiv...

If you are looking for stocks that are well positioned to maintain their recent uptrend, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price St...

Amneal (AMRX) Q2 EPS Jumps 56%

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Anastasios G. Konidaris - Executive VP & CFO Anthony DiMeo - Head of Investo...

While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to ...

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.

Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.